Duchenne News Tags: ITF Therapeutics

August 26, 2025
On August 25, 2025, ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, announced publication of positive long-term safety and efficacy data for givinostat as a treatment for Duchenne muscular dystrophy...
April 30, 2025
On April 25, 2025, ITF Therapeutics announced that the Committee for Medicinal Products (CHMP) of the European Medicines Agency (EMA) recommended granting a conditional marketing authorization for DUVYZAT® (givinostat) for...
March 20, 2025
On March 17, 2025, ITF Therapeutics announced the presentation of seven abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held March 16-19, 2025, in Dallas, Texas....
June 24, 2024
DUVYZAT is a prescription medicine that is used for the treatment of Duchenne muscular dystrophy in people 6 years of age and older.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open